Effects of a Chinese herbal health formula, "gan-Lu-Yin", on angiogenesis

Journal of Agricultural and Food Chemistry

Volumn 58, Issue 13, 2010, Pages 7685-7692

  Pan, Chun Hsu ^a   Hsieh, I Chun ^a   Liu, Fon Chang ^a   Hsieh, Wen Tsong ^a   Sheu, Ming Jyh ^a   Koizumi, Ayano ^a   Wu, Chieh Hsi ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anglogenesis; Gan Lu Yin; Vascular endothelial cells

Indexed keywords

ANGIOGENESIS INHIBITOR; HERBACEOUS AGENT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL; ARTICLE; CELL CULTURE; CHICK EMBRYO; CHORIOALLANTOIS; DRUG EFFECT; ENDOTHELIUM CELL; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; VASCULARIZATION; DRUG EFFECTS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DRUGS, CHINESE HERBAL; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954550287     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf1002254     Document Type: Article

References (31)

1. Folkman, J. Tumor angiogenesis and tissue factor. Nat. Med. 1996, 2, 167-168.
2. Hamano, Y.; Kalluri, R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem. Biophys. Res. Commun. 2005, 333, 292-298.
3. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27-31.
4. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
5. Tassi, E.; Wellstein, A. Tumor angiogenesis: initiation and targeting: therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal, adenocarcinomas. Cancer Res. Treat. 2006, 38, 189-197.
6. Scappaticci, F. A. Mechanisms and future directions for angiogenesisbased cancer therapies. J. Clin. Oncol. 2002, 20, 3906-3927.
7. Jubb, A. M.; Oates, A. J.; Holden, S.; Koeppen, H. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 2006, 5, 626-635.
8. Chao, J. C.; Chiang, S. W.; Wang, C. C.; Tsai, Y. H.; Wu, M. S. Hot water-extracted Lycium barbarum and Rehmannia glutinosa inhibit proliferation and induce apoptosis of hepatocellular carcinoma cells. World J. Gastroenterol. 2006, 12, 4478-4484.
9. Kumagai, T.; Muller, C. I.; Desmond, J. C.; Imai, Y.; Heber, D.; Koeffler, H. P. Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leuk. Res. 2007, 31, 523-530.
10. Ye, F.; Jiang, S.; Volshonok, H.; Wu, J.; Zhang, D. Y. Molecular mechanism of anti-prostate cancer activity of Scutellaria baicalensis extract. Nutr. Cancer 2007, 57, 100-110.
11. Lin, I. H.; Lee, M. C.; Chuang, W. C. Application of LC/MS and ICP/MS for establishing the fingerprint spectrum of the traditional Chinese medicinal preparation Gan-Lu-Yin. J. Sep. Sci. 2006, 29, 172-179.
12. Liu, J. J.; Huang, T. S.; Cheng, W. F.; Lu, F. J. Baicalein and baicalin are potent inhibitors of angiogenesis: inhibition of endothelial, cell proliferation, migration and differentiation. Int. J. Cancer 2003, 106, 559-565.
13. Hsieh, Y. C.; Hsieh, S. J.; Chang, Y. S.; Hsueh, C. M.; Hsu, S. L. The lipoxygenase inhibitor, baicalein, modulates cell adhesion and migration by up-regulation of integrins and vinculin in rat heart endothelial cells. Br. J. Pharmacol. 2007, 151, 1235-1245.
14. Ikezoe, T.; Chen, S. S.; Heber, D.; Taguchi, H.; Koeffler, H. P. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 2001, 49, 285-292.
15. Ma, Z.; Otsuyama, K.; Liu, S.; Abroun, S.; Ishikawa, H.; Tsuyama, N.; Obata, M.; Li, F. J.; Zheng, X.; Maki, Y.; Miyamoto, K.; Kawano, M. M. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 2005, 105, 3312-3318.
16. Sun, Y.; Lu, N.; Ling, Y.; Gao, Y.; Chen, Y.; Wang, L.; Hu, R.; Qi, Q.; Liu, W.; Yang, Y.; You, Q.; Guo, Q. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur. J. Pharmacol. 2009, 603, 22-28.
17. Lin, C. M.; Chang, H.; Chen, Y. H.; Wu, I. H.; Chiu, J. H. Wogonin inhibits IL-6-induced angiogenesis via down-regulation of VEGF and VEGFR-1, not VEGFR-2. Planta Med. 2006, 72, 1305-1310.
18. Lu, N.; Gao, Y.; Ling, Y.; Chen, Y.; Yang, Y.; Gu, H. Y.; Qi, Q.; Liu, W.; Wang, X. T.; You, Q. D.; Guo, Q. L. Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. Life Sci. 2008, 82, 956-963.
19. Schindler, R.; Mentlein, R. Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J. Nutr. 2006, 136, 1477-1482.
20. Kobayashi, S.; Miyamoto, T.; Kimura, I.; Kimura, M. Inhibitory effect of isoliquiritin, a compound in licorice root, on angiogenesis in vivo and tube formation in vitro. Biol. Pharm. Bull. 1995, 18, 1382-1386.
21. Reif, M.; LeJeune, S.; Scott, P. A.; Fox, S.; Smith, K.; Leek, R.; Moghaddam, A.; Whitehouse, R.; Bicknell, R.; Harris, A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997, 57, 963-969.
22. Jin, U. H.; Lee, J. Y.; Kang, S. K.; Kim, J. K.; Park, W. H.; Kim, J. G.; Moon, S. K.; Kim, C. H. A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci. 2005, 77, 2760-2769.
23. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6, 389-395.
24. Ferrara, N.; Gerber, H. P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001, 106, 148-156.
25. Ivy, S. P.; Wick, J. Y.; Kaufman, B. M. An overview of smallmolecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 2009, 6, 569-579.
26. Kiselyov, A.; Balakin, K. V.; Tkachenko, S. E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Inyest. Drues 2007, 16, 83-107.
27. Zhong, H.; Bowen, J. P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr. Top. Med. Chem. 2007, 7, 1379-1393.
28. Moscatelli, D.; Presta, M.; Joseph-Silverstein, J.; Rifkin, D. B. Both normal and tumor cells produce basic fibroblast growth factor. J. Cell. Physiol. 1986, 129, 273-276.
29. Ferrara, N.; Houck, K.; Jakeman, L.; Leung, D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 1992, 13, 18-32.
30. Uehara, H. Angiogenesis of prostate cancer and antiangiogenic therapy. J. Med. Invest. 2003, 50, 146-153.
31. Nie, D.; Krishnamoorthy, S.; Jin, R.; Tang, K.; Chen, Y.; Qiao, Y.; Zacharek, A.; Guo, Y.; Milanini, J.; Pages, G.; Honn, K. V. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J. Biol. Chem. 2006, 281, 18601-18609.